TY - JOUR T1 - De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report JF - medRxiv DO - 10.1101/2021.11.08.21266069 SP - 2021.11.08.21266069 AU - Shiv Gandhi AU - Jonathan Klein AU - Alexander Robertson AU - Mario A. Peña-Hernández AU - Michelle J Lin AU - Pavitra Roychoudhury AU - Peiwen Lu AU - John Fournier AU - David Ferguson AU - Shah A. Mohamed Bakhash AU - M. Catherine Muenker AU - Ariktha Srivathsan AU - Elsio A. Wunder, Jr AU - Nicholas Kerantzas AU - Wenshuai Wang AU - Anna Pyle AU - Craig B. Wilen AU - Onyema Ogbuagu AU - Alexander L. Greninger AU - Akiko Iwasaki AU - Wade L. Schulz AU - Albert I. Ko Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/09/2021.11.08.21266069.abstract N2 - SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. We present a case of an immunocompromised patient with acquired B-cell deficiency who developed an indolent, protracted course of SARS-CoV-2 infection. Remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. Whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase which was not present in pre-treatment specimens. In vitro experiments demonstrated that the mutation conferred a ∼6-fold increase in remdesivir IC50 but resulted in a fitness cost in the absence of remdesivir. Sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. Although the fitness cost observed in vitro may limit the risk posed by E802D, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection.Competing Interest StatementALG reports institutional central testing contracts from Abbott and research grants from Merck and Gilead, outside of the proposed work. AIK received consulting fees from Tata Sons and is recipient of grants on COVID-19 from Merck, Regeneron and Serimmune all of which are outside the submitted work. OO received consulting fees from Gilead and ViiV, as well as research support and honoraria from Gilead, outside of the submitted work. WLS is a consultant for Hugo Health, founder of Refactor Health and is recipient of grants on COVID-19 from Merck and Regeneron, all of which are outside the submitted work.Funding StatementThis study was supported by the Beatrice Kleinberg Neuwirth Fund; the Sendas Family Fund, Yale School of Public Health; and Department of Internal Medicine at the Yale School of Medicine. SG was supported by a grant from the National Institutes of Health (2T32AI007517-21A1). C.B.W. was supported by Burroughs Welcome Fund, Ludwig Family Foundation, and Mathers Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was also approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690, 2000029277). Informed consent was obtained from both the patient and healthcare workers. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data are available under NCBI BioProject no. PRJNA774781 https://www.ncbi.nlm.nih.gov/bioproject/?term=774781 ER -